Sarepta Therapeutics Beheer
Beheer criteriumcontroles 4/4
De CEO Sarepta Therapeutics is Doug Ingram, benoemd in Jun2017, heeft een ambtstermijn van 7.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.66M, bestaande uit 48.1% salaris en 51.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.41% van de aandelen van het bedrijf, ter waarde $ 48.03M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 8.5 jaar.
Belangrijke informatie
Doug Ingram
Algemeen directeur
US$1.7m
Totale compensatie
| Percentage CEO-salaris | 48.1% |
| Dienstverband CEO | 7.4yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 3.9yrs |
| Gemiddelde ambtstermijn bestuur | 8.5yrs |
Recente managementupdates
Recent updates
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20
The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$47m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
| Sep 30 2019 | n/a | n/a | -US$620m |
| Jun 30 2019 | n/a | n/a | -US$570m |
| Mar 31 2019 | n/a | n/a | -US$403m |
| Dec 31 2018 | US$1m | US$650k | -US$362m |
| Sep 30 2018 | n/a | n/a | -US$245m |
| Jun 30 2018 | n/a | n/a | -US$216m |
| Mar 31 2018 | n/a | n/a | -US$170m |
| Dec 31 2017 | US$57m | US$338k | -US$51m |
Compensatie versus markt: De totale vergoeding ($USD 1.66M ) Doug } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.88M ).
Compensatie versus inkomsten: De vergoeding van Doug is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Doug Ingram (61 yo)
7.4yrs
Tenure
US$1,661,338
Compensatie
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.4yrs | US$1.66m | 0.41% $ 48.0m | |
| Executive VP & CFO | 3.9yrs | US$3.71m | 0.036% $ 4.2m | |
| Executive VP & Chief Technical Operations Officer | 1.9yrs | US$3.52m | 0.018% $ 2.1m | |
| Executive VP | 3.9yrs | US$3.72m | 0.076% $ 8.9m | |
| Executive VP | 3.9yrs | US$3.58m | 0.018% $ 2.1m | |
| Executive Director of Investor Relations and Corporate Communications | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief People Officer | 3.1yrs | geen gegevens | geen gegevens | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 5.2yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Customer Officer | 3.9yrs | geen gegevens | 0.023% $ 2.7m | |
| Senior VP | 1.8yrs | geen gegevens | geen gegevens | |
| Controller & VP | 7.7yrs | US$911.89k | geen gegevens | |
| Senior Manager of Investor Relations | no data | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
50yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SRPT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.4yrs | US$1.66m | 0.41% $ 48.0m | |
| Independent Chairwoman | 15.7yrs | US$594.99k | 0.21% $ 24.5m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 14.4yrs | US$546.99k | 0.022% $ 2.6m | |
| Independent Director | 9.4yrs | US$563.65k | 3.33% $ 391.3m | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 5yrs | geen gegevens | geen gegevens | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | geen gegevens | geen gegevens | |
| Independent Non-Employee Director | 9.4yrs | US$553.34k | 0.017% $ 2.0m | |
| Member of Strategic & Scientific Advisory Board | 7.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Strategic & Scientific Advisory Board | 7.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 5yrs | geen gegevens | geen gegevens |
8.5yrs
Gemiddelde duur
71yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SRPT wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.5 jaar).